European annals of allergy and clinical immunology最新文献_第2页

Baricitinib for atopic dermatitis in real life: effectiveness, safety profile, and adherence. 巴利昔尼治疗特应性皮炎的实际效果：有效性、安全性和依从性。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-09-24 DOI: 10.23822/EurAnnACI.1764-1489.362

J Sanchez, M Velásquez, M F Ordoñez

引用次数: 0

Stress in Brazilian patients with inborn errors of immunity during the SARS-CoV-2 pandemic. SARS-CoV-2 大流行期间巴西先天性免疫错误患者的压力。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-09-10 DOI: 10.23822/EurAnnACI.1764-1489.361

L Salvador Schmid, C Sanchez Aranda, L Novaes Teixeira, R R Leite Guimarães, D Solé, G F Wandalsen

引用次数: 0

Severe CSU with low total IgE levels: is the response to omalizumab always delayed or absent? 总 IgE 水平较低的严重 CSU：对奥马利珠单抗的反应是否总是延迟或缺失？

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-09-05 DOI: 10.23822/EurAnnACI.1764-1489.360

R Asero

引用次数: 0

Allergen immunotherapy effectiveness in specific nasal reactivity of children with local allergic rhinitis. 过敏原免疫疗法对局部过敏性鼻炎患儿特异性鼻腔反应的疗效。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-09-02 DOI: 10.23822/EurAnnACI.1764-1489.358

G Loureiro, B Tavares, I Farinha, F Cunha, A Todo-Bom

{"title":"Allergen immunotherapy effectiveness in specific nasal reactivity of children with local allergic rhinitis.","authors":"G Loureiro, B Tavares, I Farinha, F Cunha, A Todo-Bom","doi":"10.23822/EurAnnACI.1764-1489.358","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.358","url":null,"abstract":"Summary: Background. Allergen immunotherapy (AIT) is the only disease-modifying treatment in allergy. Its efficacy has been demonstrated in the treatment of Local Allergic Rhinitis (LAR) in adults. This study intends to evaluate the effectiveness of AIT in specific nasal reactivity of paediatric patients with LAR. Methods. Patients diagnosed with LAR to Dermatophagoides pteronyssinus (Dp) were submitted to subcutaneous AIT (SCIT) (depigmented-polymerized Dp allergen extracts) for 3 years. Nasal allergen challenge (NACs) with Dp extract were performed before and 3 years after AIT. NAC response was assessed with peak nasal inspiratory flow (PNIF) and symptom score of Lebel. NACs were considered positive when there was a flow decrease of ≥ 20% in PNIF and a score of symptoms ≥ 3 points. Demographic data and NAC results were analysed. Results. We included 32 paediatric patients (mean age 9.9±3.08 years, 18 female) and 10 adult patients, (mean age 30.4±12.2 years, 7 female). The symptom score obtained at the 1st minute, 5th minute, 15th minute and 30th minute in response to NAC, were reduced after AIT. The nasal inspiratory flow decrease induced by NAC was also reduced after AIT. This reduction in nasal reactivity was observed in paediatric and in adult patients, both with statistical significance. Conclusions. AIT induced a decrease in Dp-nasal specific reactivity in children with LAR. This decline of nasal response to allergen exposure, after AIT treatment, emphasis the interest of this therapeutic approach in LAR, even in paediatric patients.","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Venom immunotherapy in clinical practice: comparison of two ultra-rush protocols. 临床实践中的毒液免疫疗法：两种超快速疗法的比较。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-09-02 DOI: 10.23822/EurAnnACI.1764-1489.359

R Moço Coutinho, A M Mesquita, J L Plácido, A Coimbra

{"title":"Venom immunotherapy in clinical practice: comparison of two ultra-rush protocols.","authors":"R Moço Coutinho, A M Mesquita, J L Plácido, A Coimbra","doi":"10.23822/EurAnnACI.1764-1489.359","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.359","url":null,"abstract":"Summary: Background. Ultra-rush venom immunotherapy protocols have shown to be a safe and effective approach to prevent the occurrence of systemic reactions after hymenoptera stings. The aim was to describe our experience with two ultra-rush protocols - a five-step with 1 µg starting dose and a six-step with 0.1 µg starting dose, as well as to compare their safety profile. Methods. This is a retrospective study of all the patients who underwent VIT with honey bee or wasp venom between January 2008 and December 2021, in our department. Results. A total of 110 patients was included, with 109 patients (99%) completing the protocol. A total of 63 (57%) patients had no local or systemic reactions. Most systemic reactions occurred with 20 µg or higher doses (24, 83%). There were no documented grade IV systemic reactions (Mueller grading). No differences were found in local or systemic reactions regarding sex, atopy, β-blocker medication, the severity of the index reaction, ID test positivity, levels of total IgE, specific IgE and tryptase (all p > 0.05). Younger age, treatment with bee VIT or being a beekeeper were associated with more systemic reactions (p = 0.035, 0.006 and 0.047, respectively). No statistical differences in the number of local and systemic reactions were found when comparing both protocols (p = 1.000). Conclusions. Ultra-rush protocols are safe and effective, but systemic reactions are to be expected, especially with honeybee. Our data supports that ACE inhibitors do not compromise safety. Beginning with 1 µg is safe and can save time and resources.","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Allergens weaning: what is missing from commercial baby food? 过敏原断奶：商业婴儿食品中缺少什么？

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-09-02 DOI: 10.23822/EurAnnACI.1764-1489.357

R Barbosa Silva, A Moreira, B Pimenta, I Pádua

{"title":"Allergens weaning: what is missing from commercial baby food?","authors":"R Barbosa Silva, A Moreira, B Pimenta, I Pádua","doi":"10.23822/EurAnnACI.1764-1489.357","DOIUrl":"https://doi.org/10.23822/EurAnnACI.1764-1489.357","url":null,"abstract":"Summary: Background. Current recommendations for infant weaning suggest introducing common food allergens by the age of 12 months. While homemade meals are advisable, there is a notable demand for commercially available complementary foods (CACF). Furthermore, emerging evidence suggests a potential link between the consumption of ultra-processed products and the incidence of allergic diseases. This study aimed to examine the presence of the fourteen main food allergens in CACF ingredients through label analysis and evaluate their extent of processing. Methods. Between January and February 2024, labels of all CACF found in infant feeding sections of 10 Portuguese grocery retailers were analyzed. CACF were categorized based on the NOVA food classification system's processing levels. Milk formulas, products for children over 15 months, and those for children with food allergies or intolerances were excluded Results. Of the 492 products analysed, 132 contained wheat and 112 contained milk. 16 products included fish and 6 contained egg. Soy was listed as an ingredient in 11 products, mainly as soy lecithin. Only 2 product contained nuts, and 1 product contained peanuts. None of the products contained the remaining six allergens. The majority of milk- and wheat-containing products were classified as ultra-processed and contained added sugars and/or sweeteners. Conclusions. Despite the current guidelines, commercial baby foods often lack major allergens, namely nuts and peanuts, eggs, and shellfish. Our results underscore the need for healthy, age-appropriate, minimally processed products that incorporate rather than exclude major food allergens.","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hereditary angioedema: 24 years of experience in a Portuguese reference center. 遗传性血管性水肿：葡萄牙参考资料中心 24 年的经验。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-09-01 Epub Date: 2022-12-14 DOI: 10.23822/EurAnnACI.1764-1489.278

C Varandas, L Esteves Caldeira, S L Silva, C Costa, R Limão, M I Silva, A Lopes, J Caiado, J Cosme, E Alonso, J Marcelino, F Cabral Duarte, N P Fernandes, M Neto, E Pedro, M Branco Ferreira, A Spínola Santos

{"title":"Hereditary angioedema: 24 years of experience in a Portuguese reference center.","authors":"C Varandas, L Esteves Caldeira, S L Silva, C Costa, R Limão, M I Silva, A Lopes, J Caiado, J Cosme, E Alonso, J Marcelino, F Cabral Duarte, N P Fernandes, M Neto, E Pedro, M Branco Ferreira, A Spínola Santos","doi":"10.23822/EurAnnACI.1764-1489.278","DOIUrl":"10.23822/EurAnnACI.1764-1489.278","url":null,"abstract":"Summary: Background.Hereditary angioedema (HAE) poses a high burden of disease, being its epidemiological and clinical data heterogeneous among countries, with no recent published studies concerning Portuguese patients. Therefore, we aimed to raise awareness of HAE and to contribute to clinical knowledge. Methods. An observational, descriptive, retrospective, and cross-sectional study was performed, that included a cohort of 126 patients followed in a single Portuguese Center. Results. We observed a high prevalence of HAE-C1-INH type II (45.2% of patients). Most HAE patients (67.4%) presented the initial manifestations of the disease before adulthood, at a mean age of 12.6 ± 8.4 years. However, we found a long delay in HAE diagnosis, especially in those without family history (mean 20.7 ± 17.3 years). Stress was the most common trigger, followed by trauma and infection. Symptoms involving different systems were increasingly reported with increased disease duration. Cutaneous symptoms (95.0%) were more frequent, followed by gastrointestinal (80.7%), and respiratory symptoms (50.4%). HAE symptoms led to abdominal surgery in 22 (17.5%) patients and induced laryngeal edema requiring intubation/tracheostomy in 8 (6.3%) patients. Most patients were under long-term prophylaxis, mainly with attenuated androgens (62.7% of patients). Conclusions. The correct distinction between HAE and other common causes of angioedema is critical, allowing reduction of diagnostic delay, improvement of adequate management, and ultimately improving outcomes and quality of life of HAE patients.","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10705432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Variables predicting clinical remission among adults with severe asthma treated with biologic agents. 预测接受生物制剂治疗的成人重症哮喘患者临床缓解的变量。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-09-01 Epub Date: 2023-12-06 DOI: 10.23822/EurAnnACI.1764-1489.318

S Yeşilkaya, K Aksu, G Tuğçe Vural Solak, O Akkale, O Telli, H C Tuğlu, G Köycü Buhari, S N Bahçecioğlu, S Demir

{"title":"Variables predicting clinical remission among adults with severe asthma treated with biologic agents.","authors":"S Yeşilkaya, K Aksu, G Tuğçe Vural Solak, O Akkale, O Telli, H C Tuğlu, G Köycü Buhari, S N Bahçecioğlu, S Demir","doi":"10.23822/EurAnnACI.1764-1489.318","DOIUrl":"10.23822/EurAnnACI.1764-1489.318","url":null,"abstract":"Summary: Background. Although biologic agents promise a short- to medium-term remission in asthma, it is unclear whether they can fundamentally alter disease course and achieve long-term remission. We aimed to investigate the clinical remission success of biologics in patients with severe asthma and the factors associated with remission. Methods. Adults followed-up due to severe asthma who were treated with mepolizumab or omalizumab were included in the study. Sociodemographic and clinical characteristics were reviewed. Subjects with and without clinical remission at 12 and 36 months were identified. Comparisons between the groups were made with univariate and multivariable analyses. Results. Seventy-four patients were included in the study. The mean age of subjects was 51.85 (standard deviation: 11.43) years, and 50 (67.57%) were females. The 12- and 36-month remission rates were 72.97% and 51.79%, respectively. Patients with and without remission were similar in terms of age and gender distribution. FEV1% predicted (p = 0.009) and FEV1/FVC ratio (p = 0.039) were significantly higher in those with remission at 12 months compared to those without. FEV1 (p less than 0.001), FEV1% predicted (p less than 0.001) and FEV1/FVC ratio (p = 0.004) were significantly higher in those with remission at 36 months compared to those without. Multivariable logistic regression revealed that higher FEV1% predicted was the only factor independently associated with remission for both time points. Conclusions. Omalizumab and mepolizumab provide significant clinical remission rates in severe asthma. FEV1% predicted is a variable that can independently predict clinical remission among severe asthmatics receiving biologic agents.","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138487067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The impact of a drug allergy label in an internal medicine ward. 药物过敏标签对内科病房的影响。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-09-01 Epub Date: 2023-03-28 DOI: 10.23822/EurAnnACI.1764-1489.293

P Simão Coelho, G Martins Dos Santos, M Mikovic, J Oliveira, S Rosa, E Silva, P Leiria Pinto

{"title":"The impact of a drug allergy label in an internal medicine ward.","authors":"P Simão Coelho, G Martins Dos Santos, M Mikovic, J Oliveira, S Rosa, E Silva, P Leiria Pinto","doi":"10.23822/EurAnnACI.1764-1489.293","DOIUrl":"10.23822/EurAnnACI.1764-1489.293","url":null,"abstract":"Summary: Background. Drug hypersensitivity reactions are presumably immune-mediated reactions that cause reproducible signs and/or symptoms. Overdiagnosis of drug allergy, frequently self-reported, is common and carries significant limitations. We intended to analyze the frequency and impact of drug allergy in hospitalized patients. Methods. A retrospective study was conducted in an Internal Medicine ward at a tertiary hospital in Portugal. All patients with a drug allergy report admitted within a 3-year period were included. Data were collected from their electronic medical records. Results. We found that 15.4% of patients had a report of drug allergy, with antibiotics being the most common (56.4%), followed by non-steroidal anti-inflammatory drugs (21.7%) and radiocontrast media (7.0%). The allergy report affected the clinical approach of 14.5% of patients by motivating the use of second-line agents, or the eviction of necessary procedures. The usage of alternative antibiotics entailed a cost increase of 2.4 times. There were 14.7% of patients to whom the suspected drug was administered: 87.0% tolerated and 13.0% developed a reaction. Only 1.9% were referred to our Allergy and Clinical Immunology department and proceeded in their allergy study. Conclusions. In this study, a considerable number of patients had a drug allergy label on their records. This label contributed to an increase in the cost of treatment, or the avoidance of necessary exams. However, disregarding an allergy record may lead to potentially life-threatening reactions that proper risk assessment could avoid. Further investigation should always be part of the follow-up routine of these patients, and better articulation between departments should be encouraged.","PeriodicalId":11890,"journal":{"name":"European annals of allergy and clinical immunology","volume":null,"pages":null},"PeriodicalIF":2.6,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9199396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Salt dependent aquagenic urticaria: nine new cases and proposal for a diagnostic work-up. 盐依赖性水生荨麻疹：九个新病例和诊断工作建议。

IF 2.6

European annals of allergy and clinical immunology Pub Date : 2024-09-01 Epub Date: 2024-05-28 DOI: 10.23822/EurAnnACI.1764-1489.343

R Gallo, I Trave, G Gasparini, R Castelli, G Merlo, A Parodi, E Cozzani

引用次数: 0